Upregulation of this antisense RNA is associated with metastasis in breast cancer and other cancers, while its depletion reduces the proliferation and migration of cancer cells, thus implicating MAPT-AS1 as a therapeutic target for the treatment of ER-negative breast cancers [179]. The gene discussed is MAPT; the disease is breast cancer.